Outsourcing to CROs: Expediting Clinical Operations or Oversight Nightmare?

April 28, 2020
Oracle Health Sciences

Sponsored Content

Simply handing off multi-million-dollar studies to CROs without carefully crafted plans for communications and reporting operational data as the study unfolds is hardly a wise move, yet what kind of oversight is needed? Live: Tuesday, Apr. 28, 2020 1pm EDT | 12pm CDT | 10am PDT On demand available after airing until Apr. 28, 2021. Register free

Register free: http://www.appliedclinicaltrialsonline.com/act_w/outsourcing

Event Overview: 

As the complexity of clinical trials continues to increase the importance of contract research organizations (CROs) to the pharmaceutical industry has increased significantly. Outsourcing allows pharmaceutical companies to utilize on-demand services, improving operational efficiencies by accessing therapeutic expertise and geographic reach. This reflects a sharper focus on core competencies and a shift to allow CROs to manage and conduct clinical trials.

The relationship between sponsors and CROs is strengthening as outsourcing becomes a clinical trial mainstay. Yet, outsourcing of clinical trials introduces additional complexities around quality, oversight, collaboration, and governance. Communication and transparency are required to move the clinical trial forward efficiently, but how can you do this when you’re working with multiple CROs all using inconsistent reporting conventions?

Simply handing off multi-million-dollar studies to CROs without carefully crafted plans for communications and reporting operational data as the study unfolds is hardly a wise move, yet what kind of oversight is needed?

Key Learning Objectives:

In this webcast we will explore:

  • What key metric components you need to define for your functional outsourcing

  • How you can define quality tolerance limits for each functional area

  • How Sponsors and CROs can have a common real-time view on progress and compliance without the need for micromanaging

  • Limitations in current approaches to outsourcing with regards to oversight

  • Why management direction is critical in efforts to jump-start overall performance optimization of vendor outsourcing

  • The need to standardize and automate vendor oversight in order to drive down costs and complexities

Speakers: Andy Lawton, Consultant, Risk Based Approach Ltd

Keith Dorricott, Director, Dorricott Metrics & Process Improvement Ltd

Elvin Thalund, Director, Industry Strategy, Oracle Health Sciences

Time and date: Tuesday, Apr. 28, 2020 1pm EDT | 12pm CDT | 10am PDT

On demand available after airing until Apr. 28, 2021.

Sponsor: Oracle Health Sciences

Register free: http://www.appliedclinicaltrialsonline.com/act_w/outsourcing

Related Content:

Webcasts